Study of the role of microRNAs as circulating biomarkers in hepatocellular carcinoma

Vianello, Clara (2026) Study of the role of microRNAs as circulating biomarkers in hepatocellular carcinoma, [Dissertation thesis], Alma Mater Studiorum Università di Bologna. Dottorato di ricerca in Sport, salute e benessere, 38 Ciclo.
Documenti full-text disponibili:
[thumbnail of Vianello_Clara_tesi.pdf] Documento PDF (English) - Accesso riservato fino a 15 Giugno 2029 - Richiede un lettore di PDF come Xpdf o Adobe Acrobat Reader
Disponibile con Licenza: Creative Commons: Attribuzione 4.0 (CC BY 4.0) .
Download (9MB) | Contatta l'autore

Abstract

Hepatocellular carcinoma (HCC) represents the third leading cause of cancer-related death worldwide. Although immunotherapy has revolutionized HCC management, sorafenib and lenvatinib remain first-line options for advanced-HCC, particularly in immunotherapy-ineligible patients. Transarterial chemoembolization (TACE) is recommended for intermediate-HCC stages. However, acquired resistance limits treatment efficacy, and the lack of predictive biomarkers remains an unmet clinical need. Despite the well-known role of microRNA in HCC progression, metabolic reprogramming and drug response, the mechanisms driving sorafenib and TACE resistance remain poorly understood. Furthermore, while CXCL3, miR-30e-3p, and miR-22 are emerging as potential therapeutic targets, their predictive role is not yet fully elucidated. My thesis project aimed at evaluating the predictive potential of circulating miR-22 in response to TACE and sorafenib treatment in intermediate- and advanced-stage HCC patient cohorts, respectively. In addition, my PhD project aimed at assessing the predictive value of the miR-30e-3p/CXCL3 axis in the early development of sorafenib resistance in HCC patients. Firstly, I demonstrated CXCL3 targeting by miR-30e-3p in HCC, reporting its effect in sorafenib resistance in the DEN-HCC rat model. I evaluated CXCL3 and miR-30e-3p as potential circulating biomarkers of sorafenib response in HCC patients ongoing sorafenib treatment. Furthermore, I characterized miR-22 as a serum biomarker predictive of sorafenib response in a cohort of sorafenib-treated HCC patients and evaluated miR-22 effects in the DEN-HCC rat model. Moreover, I reported miR-22 as a promising circulating biomarker of TACE response. I also demonstrated WEE1 targeting by miR-22 and the involvement of miR-22/WEE1 axis in cell proliferation, apoptosis and DNA damage following doxorubicin treatment under hypoxia-like conditions. Collectively, these data highlight the potential role of CXCL3, miR-30e-3p and miR-22 as circulating biomarkers of sorafenib response. Furthermore, miR-22 emerged as an early circulating biomarker of TACE nonresponse while the miR-22/WEE1 axis represents an interesting therapeutic target for combined strategies.

Abstract
Tipologia del documento
Tesi di dottorato
Autore
Vianello, Clara
Supervisore
Co-supervisore
Dottorato di ricerca
Ciclo
38
Coordinatore
Settore disciplinare
Settore concorsuale
Parole chiave
HCC, microRNA, sorafenib, TACE, biomarker
Data di discussione
15 Luglio 2026
URI

Altri metadati

Gestione del documento: Visualizza la tesi

^